www.neurologiepropraxi.cz / Neurol. praxi. 2024;25(3):224-229 / NEUROLOGIE PRO PRAXI 229 PŘEHLEDOVÉ ČLÁNKY Nové možnosti liečby spektra ochorení neuromyelitis optica (NMOSD) LITERATÚRA 1. Brod SA. Review of approved NMO therapies based on me‑ chanism of action, efficacy and long‑term effects. Mult Scler Relat Disord. 2020;46:102538. 2. Costello F, Burton JM. Contemporary management challen‑ ges in seropositive NMOSD. J Neurol. 2022:1-8. 3. Cree BA, Lamb S, Morgan K, Chen A, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64:1270-1272. 4. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the tre‑ atment of neuromyelitis optica spectrum disorder (N‑MOmen‑ tum): a double‑blind, randomised placebo‑controlled phase 2/3 trial. The Lancet. 2019;394:1352-1363. 5. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systema‑ tic review and meta‑analysis. JAMA Neurol. 2016;73:1342-1348. 6. Giovannelli J, Ciron J, Cohen M, et al. A meta‑analysis com‑ paring first‑line immunosuppressants in neuromyelitis optica. Ann Clin Transl Neurol. 2021;8:2025-2037. 7. Kim W and Kim HJ. An update on biologic treatments for neuromyelitis optica spectrum disorder. Expert Rev Clin Immunol. 2023;19(1):111-121. 8. Kümpfel T, Giglhuber K, Aktas O, et al. The Neuromyelitis Op‑ tica Study Group (NEMOS). Update on the diagnosis and tre‑ atment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long‑term manage‑ ment. Journal of Neurology. 2023;271(1):141-176. 9. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol. 2016;79:206-216. 10. Li R, Li C, Huang Q, et al. Immunosuppressant and neuro‑ myelitis optica spectrum disorder: optimal treatment durati‑ on and risk of discontinuation. Eur J Neurol. 2022;29:2792-2800. 11. Lin J, Xue B, Zhu R, et al. Intravenous immunoglobu‑ lin as the rescue treatment in NMOSD patients. Neurol Sci. 2021;42:3857-3863. 12. Nakashima I, Nakahara J, Yokote H, et al. Long‑term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody‑positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post‑marketing surveillance in Ja‑ pan. Ther Adv Neurol Disord. 2023;16:1-13. 13. Palace J, Wingerchuk DM, Fujihara K, et al. Benefits of eculi‑ zumab in AQP4+ neuromyelitis optica spectrum disorder: sub‑ group analyses of the randomized controlled phase 3 PREVENT trial. Mult Scler Relat Disord. 2021;47:102641. 14. Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in aqua‑ porin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93:1053-1068. 15. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aqua‑ porin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614-625. 16. Rensel M, Zabeti A, Mealy MA, et al. Long‑term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4–immunoglobulin G‑seropositive parti‑ cipants taking inebilizumab for ≥ 4 years in the N‑MOmentum trial. Mult Scler (Houndmills, Basingstoke, Engl). 2022;28:925–932. 17. Ringelstein M. ECTRIMS 2022 – ePoster. Mult Scler J. 2022;28:692-945. 18. Ringelstein M, Ayzenberg I, Harmel J, et al. Long‑term thera‑ py with interleukin 6 receptor blockade in highly active neuro‑ myelitis optica spectrum disorder. JAMA Neurol. 2015;72:756-763. 19. Siritho S, Nopsopon T, Pongpirul K. Therapeutic plasma ex‑ change vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta‑analysis. J Neurol. 2021;268:4549-4562. 20. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN1 study): a multicentre, randomised, double‑blind, placebo ‑controlled trial. Lancet Neurol. 2020;19:298-306. 21. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double‑blind, multicentre, placebo‑controlled phase 3 trial. Lancet Neurol. 2020;19:402-412. 22. Valencia‑Sanchez C, Wingerchuk DM. Emerging targe‑ ted therapies for Neuromyelitis Optica Spectrum Disor‑ ders. BioDrugs. 2021;35:7-17. 23. Wang Y, Zhong X, Wang H, et al. Batoclimab as an add‑on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. Eur J Neurol. 2022;30:195-203. 24. Wingerchuk DM, Banwell B, Bennett JL, et al. Internati‑ onal consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177-189. 25. Wingerchuk DM, Fujihara K, Palace J, et al. Long‑term safety and efficacy of eculizumab in aquaporin-4 IgG po‑ sitive NMOSD. Ann Neurol. 2021;89:1088-1098. 26. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satrali‑ zumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:2114-2124. 27. Yamamura T, Weinshenker B, Yeaman MR, et al. Long ‑term safety of satralizumab in neuromyelitis optica spec‑ trum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66:104025. 28. Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neu‑ romyelitis optica spectrum disorder (TANGO): an open ‑label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19:391-401. ODBORNÝ GARANT: doc. RNDr. MUDr. Pavel Ješina, Ph.D. POŘADATEL: Společnost SOLEN, s. r. o., ve spolupráci s Klinikou pediatrie a dědičných poruch metabolismu 1. LF UK a VFN v Praze ZLATÝ PARTNER POČET KREDITŮ 2 Registrace ZDARMA TERMÍN květen 2024 až duben 2025 dostupný na online.solen.cz ON LINE KURZ OBSAH KURZU Úvod do lyzosomálních střádavých onemocnění doc. RNDr. MUDr. Pavel Ješina, Ph.D. Niemann-Pickova choroba typu B – nové léčitelné onemocnění doc. RNDr. MUDr. Pavel Ješina, Ph.D. Gaucherova nemoc – snadno diagnostikovatelné onemocnění MUDr. Stella Reichmannová, Ph.D. Pompeho nemoc – jak odhalit typické i méně typické případy MUDr. Lívie Mensová Diskuze Našli jsme vzácného pacienta – hledejme dál
RkJQdWJsaXNoZXIy NDA4Mjc=